Testosterone After Hip Fracture: What This Trial Does, and Doesn’t, Show

Key Takeaways

• Testosterone dose doubled typical female levels, raising safety concerns.
• No improvement in 6‑minute walk distance with testosterone.
• Only one secondary outcome showed benefit, not replicated versus usual care.
• Post‑hoc subgroup findings likely chance; require larger confirmatory trials.
• Current evidence does not support prescribing testosterone for hip‑fracture rehab.

Pulse Analysis

Hip fractures are a leading cause of disability among older women, often leading to prolonged mobility loss and increased mortality. Because testosterone has anabolic effects on muscle and bone, anecdotal reports have suggested it could speed functional recovery after such injuries. This interest has been amplified online, prompting clinicians and patients to seek evidence for hormone‑based interventions that might reduce dependence on assistive devices and shorten rehabilitation timelines.

The STEP‑HI trial, published in JAMA Network Open, enrolled women 65 and older within 22 weeks of surgical repair and randomized them to three arms: supervised exercise with testosterone gel, supervised exercise with placebo gel, or enhanced usual care. The testosterone regimen produced serum levels roughly twice the normal female range, raising concerns about side effects such as hirsutism, voice deepening, and clitoral enlargement. After 24 weeks, the primary outcome—distance covered in a six‑minute walk test—showed no statistically significant difference between the testosterone‑exercise and placebo‑exercise groups. Among ten secondary endpoints, only the Short Physical Performance Battery favored testosterone, and that benefit vanished when compared to the usual‑care cohort, indicating a likely chance finding.

Clinicians should interpret these results as a clear signal that high‑dose testosterone does not confer functional advantage in post‑hip‑fracture recovery and may introduce avoidable risks. The study also illustrates the pitfalls of over‑interpreting secondary or post‑hoc analyses, especially in small, multi‑arm trials. Future research may explore lower, physiologic testosterone doses or alternative anabolic agents, but until larger, rigorously designed trials demonstrate safety and efficacy, prescribing testosterone for hip‑fracture rehabilitation remains unsupported.